Novartis AG (NVSEF)
| Market Cap | 234.87B |
| Revenue (ttm) | 53.22B |
| Net Income (ttm) | 12.86B |
| Shares Out | n/a |
| EPS (ttm) | 6.38 |
| PE Ratio | 18.26 |
| Forward PE | 13.72 |
| Dividend | 3.97 (3.35%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 333 |
| Average Volume | 8,261 |
| Open | 118.66 |
| Previous Close | 120.50 |
| Day's Range | 118.66 - 118.66 |
| 52-Week Range | 94.70 - 126.34 |
| Beta | 0.53 |
| RSI | 56.15 |
| Earnings Date | Jul 17, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsNews
Divi’s Laboratories shares fall 3% after MSN wins Entresto patent case
Shares of Divi’s Laboratories fell 3% in early trade after MSN Laboratories secured a win in a key patent litigation case involving Novartis’s blockbuster heart failure drug Entresto (Sacubitril/Valsa...
Why Novartis Is Still A 'Buy' After 15% Surge
Novartis loses patent challenge to block MSN Pharma’s generic Entresto
Novartis loses bid to block US Entresto generic through 2026
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday.
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS) Following this important milesto...
Novartis (NVS) Gains Approval for Infant Malaria Treatment
Novartis (NVS) Gains Approval for Infant Malaria Treatment
Novartis wins approval for first malaria drug for newborns
Swiss pharma group says lack of provision for small infants has led to ‘treatment gap’ in deadly disease
Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children
Novartis (NVS) on Tuesday said that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants.
Novartis gets approval for first malaria drug for babies and children
Novartis on Tuesday said it had received approval in Switzerland for Coartem, which it said was the first drug to treat malaria in babies and young children.
Novartis receives approval for first malaria medicine for newborn babies and young infants
Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, ...
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
Novartis AG (NYSE: NVS) on Thursday released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing giant cell arteritis (GCA) . Giant cell...
Novartis fails in late-stage trial for Cosentyx in giant cell arteritis
Novartis AG (NVS) Announces Phase III GCAptAIN Study Results for Cosentyx | NVS stock news
Novartis AG (NVS) Announces Phase III GCAptAIN Study Results for Cosentyx | NVS stock news
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis ...
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) | NVS Stock News
Novartis drug Cosentyx fails late-stage trial for artery disease
Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile ...
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (...
Notable Insider Move: William Meury Takes Part In Options Exercise At Incyte, Resulting In $0
Highlighted on June 30, it was unveiled in an SEC filing that Meury, Chief Executive Officer at Incyte (NASDAQ: INCY), executed a significant transaction involving the exercise of company stock optio...
Final Trades: Novartis, Sixth Street, Amazon and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Novartis, Sixth Street, Amazon and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Novartis in deal with ProFound for cardiovascular disease therapies
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen Inc. (NASDAQ: BIIB) on Wednesday announced in a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for ...
Novartis completes acquisition of Regulus Therapeutics
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common st...
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.